Gerresheimer AG
XETRA:GXI

Watchlist Manager
Gerresheimer AG Logo
Gerresheimer AG
XETRA:GXI
Watchlist
Price: 24.54 EUR 1.49% Market Closed
Market Cap: €847.6m

P/E

36.3
Current
20%
More Expensive
vs 3-y average of 30.2

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
36.3
=
Market Cap
€661.4m
/
Net Income
€23.4m

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
36.3
=
Market Cap
€661.4m
/
Net Income
€23.4m

Valuation Scenarios

Gerresheimer AG is trading above its 3-year average

If P/E returns to its 3-Year Average (30.2), the stock would be worth €20.38 (17% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-47%
Maximum Upside
+3%
Average Downside
20%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple 36.3 €24.54
0%
3-Year Average 30.2 €20.38
-17%
5-Year Average 29.1 €19.66
-20%
Industry Average 37.5 €25.36
+3%
Country Average 19.3 €13.02
-47%

Forward P/E
Today’s price vs future net income

Today's Market Cap Net Income Forward P/E
€661.4m
/
Sep 2025
€23.4m
=
36.3
Current
€661.4m
/
Dec 2025
€74.7m
=
8.8
Forward
€661.4m
/
Dec 2026
€87.4m
=
7.6
Forward
€661.4m
/
Dec 2027
€121.5m
=
5.4
Forward
€661.4m
/
Nov 2028
€186.1m
=
3.6
Forward
€661.4m
/
Nov 2029
€190.6m
=
3.5
Forward

Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.

Market Distribution

Higher than 78% of companies in Germany
Percentile
78th
Based on 2 106 companies
78th percentile
36.3
Low
0 — 13.8
Typical Range
13.8 — 29.5
High
29.5 —
Distribution Statistics
Germany
Min 0
30th Percentile 13.8
Median 19.3
70th Percentile 29.5
Max 8 582.9

Gerresheimer AG
Glance View

Gerresheimer AG, nestled in the heart of Germany, has evolved into a cornerstone of the pharmaceutical and healthcare industries. Its beginnings were humble, rooted in glass manufacturing over a century ago, but the company has since metamorphosed into a leading provider of specialized products for the global healthcare market. Today, Gerresheimer's portfolio stretches well beyond glass, encompassing a range of highly technical and innovative products. The company specializes in producing glass and plastic containers, including vials, ampoules, and cartridges, which are crucial for delivering drugs and vaccines safely to patients worldwide. Its sophisticated offerings extend to complex drug delivery devices like insulin pens and inhalers, showcasing its deep integration into the supply chains of major pharmaceutical companies. Gerresheimer's business model thrives on close partnerships with these pharmaceutical giants, crafting tailor-made solutions for diverse therapeutic areas. This strategic alignment positions it well amid growing global health needs and an aging population, driving steady demand for its high-margin products. Its operations are bolstered by an international footprint of production facilities, allowing for high-quality, efficient manufacturing and distribution. This network not only enhances its logistics but also supports the company's commitment to innovation, enabling it to meet specific regulatory and market requirements across different regions. Ultimately, Gerresheimer AG makes its mark and profits through a combination of cutting-edge technology, stringent quality standards, and strategic relationships, securing its place as a vital player in the global healthcare ecosystem.

GXI Intrinsic Value
88 EUR
Undervaluation 72%
Intrinsic Value
Price €24.54
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett